Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Investing.com - Citizens JMP has reiterated its Market Outperform rating and $91.00 price target on Halozyme Therapeutics (NASDAQ:HALO) following clarity on CMS combination drug policy. The company has demonstrated robust financial health with a perfect Piotroski Score of 9 and impressive revenue growth of 35% over the last twelve months.
The firm views the recently published final CMS guidance for 2028 IRA Medicare drug price negotiations as "a clear win" for Halozyme’s ENHANZE technology, which had faced pressure following draft guidance released in May 2025.
The final guidance makes no changes to the combination drug policy that had previously raised concerns among investors and temporarily pressured HALO shares when the draft was interpreted as potentially negative for combination products using ENHANZE.
Citizens JMP expressed confidence that ENHANZE provides "clinically meaningful benefit" to the combination drugs it enables, strengthening its positive outlook on the company’s future performance.
The research firm further noted that even if CMS revisits this topic for its 2029 policy, it does not expect any changes that would negatively impact ENHANZE royalties.
In other recent news, Halozyme Therapeutics has experienced a series of significant developments. The company reported strong earnings results for the first half of 2025, prompting Benchmark to raise its price target to $90, maintaining a Buy rating. Citizens JMP also increased its price target to $91 following Halozyme’s second-quarter financial results, which exceeded estimates and led to revised guidance for 2025. Meanwhile, H.C. Wainwright adjusted its price target to $85, influenced by Merck & Co.’s FDA approval for subcutaneous Keytruda. Morgan Stanley upgraded Halozyme to Overweight, with a new price target of $75, citing the ORPHAN Cures Act as a positive factor. Goldman Sachs, however, maintained a Neutral rating, raising its target to $56, reflecting potential impacts from the Inflation Reduction Act. These developments underscore a period of active evaluation and adjustment by various analysts regarding Halozyme’s financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.